HC Wainwright Predicts Erasca’s Q3 Earnings (NASDAQ:ERAS)

Erasca, Inc. (NASDAQ:ERAS) – Stock analysts at HC Wainwright cut their Q3 2026 EPS estimates for Erasca in a report released on Wednesday, August 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.14) per share for the quarter, down from their previous estimate of ($0.13). HC Wainwright currently has a “Buy” rating and a $22.00 target price on the stock. The consensus estimate for Erasca’s current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for Erasca’s Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.51) EPS, FY2027 earnings at ($0.58) EPS, FY2028 earnings at ($0.61) EPS, FY2029 earnings at ($0.70) EPS and FY2030 earnings at ($0.54) EPS.

Other equities research analysts also recently issued research reports about the company. Morgan Stanley boosted their price objective on Erasca from $12.00 to $21.00 and gave the company an “equal weight” rating in a report on Monday, July 20th. Wolfe Research set a $16.00 price target on shares of Erasca in a research report on Thursday, June 4th. Jefferies Financial Group restated a “buy” rating on shares of Erasca in a research note on Tuesday, July 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Erasca in a research note on Thursday, June 11th. Finally, Bank of America lifted their price objective on shares of Erasca from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Tuesday, July 14th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.91.

Erasca Stock Performance

ERAS stock opened at $17.86 on Friday. The stock’s 50 day simple moving average is $17.18 and its 200 day simple moving average is $15.00. The company has a market cap of $6.25 billion, a P/E ratio of -18.80 and a beta of 0.66. Erasca has a fifty-two week low of $1.33 and a fifty-two week high of $24.28.

Erasca (NASDAQ:ERAS) last issued its earnings results on Wednesday, August 12th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Erasca in the second quarter worth $387,544,000. VR Adviser LLC increased its holdings in Erasca by 10.1% during the 2nd quarter. VR Adviser LLC now owns 17,857,083 shares of the company’s stock worth $22,678,000 after acquiring an additional 1,640,867 shares during the period. Paradigm Biocapital Advisors LP boosted its holdings in Erasca by 4.4% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 14,159,095 shares of the company’s stock valued at $52,672,000 after purchasing an additional 599,078 shares during the period. Vanguard Group Inc. boosted its holdings in Erasca by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 12,811,832 shares of the company’s stock valued at $27,930,000 after purchasing an additional 116,235 shares during the period. Finally, Vivo Capital LLC grew its position in shares of Erasca by 31.0% during the 1st quarter. Vivo Capital LLC now owns 12,151,480 shares of the company’s stock valued at $196,611,000 after purchasing an additional 2,878,052 shares in the last quarter. Institutional investors own 67.78% of the company’s stock.

Erasca Company Profile

Erasca, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene?driven and immuno?oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.